Phytoceutical compositions from organic extracts of the Ambrosia maritima or Ambrosia hispida plants and uses thereof for treatment of cancers is described.

A method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

Disclosed herein is a herbal formulation comprising a herbal extract of Elephantopus tomentosus L and a herbal extract of Leea indica, which may be used in the treatment of cancer (e.g. colon cancer). The herbal formulation may further comprise one or more of: an extract of Clinacanthus nutans; an extract of Strobilanthes crispus L; and an extract of Callicarpa pedunculata R. Br.

The present disclosure provides use of an effective part extract of Monochasma savatieri in preparation of a drug for treating an inflammatory disease or a tumor. In the present disclosure, an effective part of Monochasma savatieri is separated and purified by various separation and purification methods (including solvent extraction, macroporous resin column chromatography, MCI column separation, and Sephadex LH-20 gel column separation) separately, to obtain the effective part extract of Monochasma savatieri. The effective part extract of Monochasma savatieri is capable of significantly inhibiting secretion of TNF-, and significantly inhibiting proliferation of breast cancer cells and lung cancer cells, thereby effectively treating the inflammatory disease or the tumor. The present disclosure provides a favorable theoretical basis for finding a drug that can effectively treat the inflammatory disease or the tumor from the Monochasma savatieri, which is of great significance to development of novel drugs.

A method of purifying cannabis derived terpenes includes first providing cannabis material having a detectable amount of tetrahydrocannabinolic acid (THCA), adding a solvent to the cannabis material, spinning the cannabis material in a centrifuge to separate crystallized THCA from a high terpene extract. Decarboxilating the THCA with heat to yield tetrahydrocannabinol. The high terpene extract is deposited into a vacuum oven to reduce pressure and volatilize terpenes from the high terpene extract. Next the terpenes are pumped into a cold trap to condense terpenes from the high terpene extract. Next, the condensed terpenes are cooled at a temperature between 50 C. and 0 C. to remove water from the condensed terpenes and yield purified terpenes. The purified terpenes are applied to an edible food product containing decarboxylated tetrahydrocannabinol. In an alternate embodiment, the tetrahydrocannabinol and the purified terpenes are combined or recombined and mixed directly into a precooked edible food product.

A purified lipid-based solution including cannabinoids is manufactured by providing a lipid solution including an array of triglycerides, cannabinoids and water soluble contaminants. Adding water to the lipid solution to create a mixture and heating the mixture in a pressure vessel to a temperature above the melting point of the lipid solution. The mixture is agitated to dissolve the water soluble contaminants and electrocoagulated. The mixture is cooled to cause the triglycerides and cannabinoids to solidify. The water is separated from the mixture to remove water soluble contaminants, precipitated contaminants, suspended solids and colloids from the mixture to yield a purified lipid solution.

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.

Use of a mulberry extract in the preparation of a product for treating and/or improving polycystic ovarian syndrome. It is demonstrated in the experiment that the mulberry twig alkaloids can reduce the ovarian weight of rats with polycystic ovarian syndrome and improve the ovarian pathology, regulate the estrous cycle of rats with polycystic ovarian syndrome in the intervention process, and can remarkably adjust the secretion level of sex hormones in rats with polycystic ovarian syndrome.

The present invention relates to inventive novel industrialized method for preparing purified extract containing more abundant active ingredients such as catalpol derivatives from the extract of Pseudolysimachion rotundum var subintegrum than that prepared by the conventional preparation method disclosed in the prior art and the therapeutics or functional health food comprising the purified extract for treating and preventing inflammatory, allergic or asthmatic disease. The purified extract showed more potent anti-inflammatory, anti-allergy and anti-asthma activity than that prepared by the conventional preparation method disclosed in the prior art through various in vivo tests such as inhibition test on the reproduction of eosinophil, the release of immunoglobulin and inflammatory chemokines in plasma and bronchoalveolar fluid as well as the suppression of airway hyperresponsiveness and goblet cell hyperplasia in a OVA-sensitized/challenged mouse model.